Markers of thrombophilia in pulmonary fibrosis complicated by pulmonary hypertension

Cite item

Full Text


Aim. To determine the role of enhanced blood coagulation in pathogenesis of pulmonary hypertension (PH) at an early stage of fibrosing alveolitis (FA).
Material and methods. Clinical, functional, roentgenological, coagulation and immunological examinations were performed in 17patients with idiopathic FA (IFA), in 6 patients with exogenic allergic alveolitis (EAA), in 15 FA patients with diffuse diseases of the connective tissue (FA-DDCT). The diagnosis was verified with high resolution computed tomography (HRCT). Lesser circulation was assessed by Doppler echocardiography. Morphological impairment of the lungs was specified in all the patients using analysis of the bronchoalveolar lavage. In 9 FA patients the diagnosis was verified at thoracoscopic biopsy of the lung. The control group consisted of 16 healthy volunteers. Thrombin-antithrombin complex (TAT) and thrombocyte factor 4 (TF-4) were estimated with ELISA as stable, highly sensitive markers of thrombophilia.
Results. The TF-4 level was elevated in all IPD patients (p < 0.05), the elevation being highest in FA-DDCT (p < 0.007). With FA progression, TF-4 concentration went down. A weak negative correlation (p < 0.047, r = -0.38) was found with average pressure in the pulmonary artery (PAAP). TAT was higher than control in all the groups (p < 0.05). Maximal TAT values were registered in EAA. If HRCT detected active inflammation and in development of irreversible fibrous changes TAT was higher vs control. A direct correlation between TAT level and PAAP was not found. Conclusion. Disorders in thrombocytic and plasmic links of hemostasis are detectable early in IPD. Stable markers of thrombophilia (TAT and TF-4) reflect activity of inflammation in FA. They can be also used as sensitive diagnostic tests for diagnosis of PH and diagnosis of patients with activated coagulation system in IPD.


  1. Коган Е. А., Корпев Б. М., Салов Ю. А. и др. Варианты и стадии течения идиопатического фиброзирующего альвеолита. Тер. арх. 1995; 5: 21-26.
  2. Путов Н. В., Илькович М. М. Фиброзирующие алызсолиты. М.: Медицина: 1986.
  3. Crouch E. Pathology of pulmonary fibrosis. Am. J. Physiol. 1990; 259: 159-184.
  4. Шаталов Н. Н., Гусейнов С. Н. Легочная гипертензия при идиопатическом фиброзирующем альиеолите. Пробл. туб. 1984; 12: 29-33.
  5. Girod С. Е. The lung in mixed connective tissue disease. Sem. Respir. Crit. Med. 1999; 20 (2): 99-108.
  6. Shen J. Y. et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol. Int. 1999; 18: 147-151.
  7. Murata I., Takenaka K., Yoshinoya S. et al. Clinical evaluation of p. h. in systemic sclerosis and related disorders. A Doppler EchoCG. Study of 135 Japanese patients. Chest 1997; 111: 36-43.
  8. Olschewski H., Ghofrani H. A. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. 1999; 160 (2): 600- 607.
  9. Rich S., Braimwald E., Grossman W. Pulmonary hypertension. In: Braimwald E., ed. Heart disease: a textbook of cardiovascular medicine. 5-th ed. Philadelphia: W. B. Saunders; 1997. 780.
  10. Weitzenblum E., Demedts M. Treatment of pulmonary hypertension in chronic obstructive pulmonary disease. Eur. Respir. Med. 1998; 7: 180-188.
  11. Федорова Т. А. Хроническое легочное сердце. В кн.: Чучалин А. Г. (ред.) Хронические обструктивные болезни легких. М.: ЗАО Изд-во "БИНОМ"; СПб: Невский диалект; 1998. 192-215.
  12. Cailes J., Winter S. et al. Defective endothelial^ mediated pulmonary vasodilatation in systemic sclerosis. Chest 1998; 144: 178-184.
  13. Stenmark K. R., Mecham R. P. Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu. Rev. Physiol. 1997;59:89-144.
  14. Higenbottam T. Pathology of pulmonary hypertension. A role of endothelial dysfunction. Chest 1994; 105 (2, suppl.).
  15. Gaine S. P., Rubin L. J. Primary pulmonary hypertension. Lancet 1998; 352:719-725.
  16. Tuder R. M., Voelkel N. F. Pulmonary hypertension and inflammation. J. Lab. Clin. Med. 1998; 132: 16-24.
  17. Gray A. G., Bishop J., Reeves R. P. et al. Partially degraded fibrinogen) stimulates fibroblast proliferation in vitro. Am. J. Respir. Cell Mol. Biol. 1995; 12: 684-690.
  18. Bar-Shavit R., Benezra M., Sabbah V. et al. Thrombin as a multifunctional protein: induction of cell adhesion and proliferation. Am. J. Respir. Cell Mol. Biol. 1992; 6: 123-130.
  19. Spencer H. Pathology of the lung. 3-rd ed. Philadelphia: W. B. Saunders; 1977. 235-240.
  20. Prat P. The lung: structure, function, and disease. Baltimore: Williams & Wilkins; 1978. 45-47.
  21. Бакеева M. Э. Легочная артериальная гипертензия и реактивность артериальных сосудов малого круга кровообращения у больных с системной склеродермией: Автореф. дис. ... канд. мед. наук. Бишкек; 1995.
  22. Orens J. В., Martinez F. J., Lynch J. P. III. Pleuropulmonary manifestations of systemic lupus erythematosus. Rheum. Dis. Clin. N. Am. 1994; 20: 159-193.
  23. Launay D., Hachulla E., Matron P. Y. et al. Depistage de l'hypertension arterielle pulmonaire au cours de la sclerodermic systemique: etude d'une cohorte de 67 patients. Rev. Med. Ir teme 2001; 22 (9): 819-829.
  24. Lee P., Langevitz C. Mortality in systemic sclerosis (sclerodej ma). Quart. J. Med.; 82: 139-148.
  25. Макацария А. Д., Бицадзе В. О. Тромбофилические ее стояния в акушерской практике. М.; 2001.
  26. Rosen Т., Kuczynski E., O'Neill L. M. et al. Plasma levels с thrombin-antithrombin complexes predict premature ruptur of the fetal membranes. Matern. Fetal. Med. 2001; 10 (5; 297-300.
  27. Von Kanel R., Le D. Т., Nelesen R. A. et al. The hypercoagula ble state in sleep apnea is related to comorbid hypertension. J Hyperte4ns. 2001; 19 (8): 1445-1451. „
  28. Jdell S., Maunder R., Fein A. M. et al. Platelet-specific alpha granule proteins and thrombospondin in bronchoalveolar lav age in the adult respiratory distress syndrome. Chest 1989; 9i (5): 1125-1132.
  29. Миррахимов М. М. Современные подходы к инструмен тальной диагностике легочной артериальной гипертен зии: количественные методы определения легочного артериального давления (часть И). Кардиология 1995; 2: 65.
  30. Ультразвуковая диагностика в кардиологии: Метод, пособие. М.: Международный центр авторских мед. технологий; 1992.
  31. Митьков В. В. Клиническое руководство по ультразвуковой диагностике. М. 1998; т. 5: 110.
  32. Reynolds T. The echocardiographer's pocket reference. Arizona Heart Institute Foundation; 1993. 160.
  33. de Boer A. C. Chemistry, measurement, and clinical significance of platelet-specific proteins. Crit. Rev. Clin. Lab. Sci. 1982; 18: 183-211.
  34. Pelzer H. Enzyme immunoassay for determination of human thrombin/antithrombin III complex. Thromb. Res. 1986; suppl. VI: 51.
  35. Pelzer H. Enzyme immunoassay for the determination of human platelet factor 4. Blut 1984; 49: 123-124.
  36. Архипова Д. В., Мухин Н. А., Корпев Б. М. и др. Легочная гипертензия при интерстициальных болезнях легких. Клин. мед. 2002; 6: 28-33.
  37. Vrij A. A., Rijken J., van Wersch J. W. J., Stockbrugger R. W. Platelet factor 4 and j}-thromboglobu!in in inflammatory bowel disease and giant cell arteritis. Eur. J. Clin. Invest. 2000; 30: 188-194.
  38. Sharpe R. J., Murphy G. F., Whitaker D. et al. Induction of local inflammation by recombinant human platelet factor-4 in the mouse. Cell. Immunol. 1991; 137 (1): 72-80.
  39. Duel T. F., Senior R. M., Chang D. et al. Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc. Natl. Acad. Sci. USA 1981; 78: 4584-4587.
  40. Yasui H., Gabazza E. C., Taguchi O. et al. Decreased protein С activation is associated with abnormal collagen turnover in the intraalveolar space of patients with interstitial lung disease. Clin. Appl. Thromb. Hemost. 2000; 6 (4): 202-205.
  41. Hiroyasu Kobayashi, Gabazza E. C., Osamu Taguchi et al. Protein С anticoagulant system in patients with interstitial lung disease. Am. J. Resir. Crit. Care Med. 1998; 157 (6): 18501854.
  42. Endersen G. K. Platelet factor 4 in patients with rheumatoid arthritis. Rheumatol. Int. 1989; 9: 19.
  43. Yamada H., lzutani R., Chihara J., Yadate T. RANTES mRNA expression in skin and colon of patients with atopic dermatitis. Int. Arch. Allergy Immunol. Ill: 19-21.
  44. Watanabe O., Natori K., Tamari M. et al. Significantly elevated expression of PF4 (platelet factor 4) and eotaxin in the NOA mouse, a model for atopic dermatitis. Jpn. Soc. Hum. Genet. 1999; 44: 173-176.
  45. Myler H. A., West J. L. Heparanase and platelet factor 4 induce smooth muscle cell proliferation and migration via bFGF release from the ECM. J. Biochem. (Tokyo) 2002; 131 (6): 913-922.
  46. Burstein S. A., Malpass T. W., Yee E. et al. Platelet factor 4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis. Br. J. Haematol. 1984; 57 (3): 383- 392.
  47. Tarn L. S., Li E. K. Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome. Lupus 1998; 7: 495-497.
  48. Keller Т., Salge U., Koning N. et al. Tissue factor is the only activator of coagulation in cultured human lung cancer cells. Lung Cancer 2001; 31 (2-3): 171-179.
  49. Kiraz S., Ertenli I., Benekli M. et al. Clinical significance of hemostatic markers and thrombomodulin in systemic lupus erythematosus: evidence for a prothrombotic state. Lupus 1999;8:737-741.
  50. Brendel-Midler K., Hahn A., Schneppenheim R., Santer R. Laboratory signs of activated coagulation are common in Henoch- Schonlein purpura. Pediatr. Nephrol. 2001; 16 (12): 1084-1088.
  51. Matsuyama W., Hashiguchi Т., Mizoguchi A. et al. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 2000; 118 (4): 948-951.
  52. Inoh M., Tokuda M., Kiuchi H. et al. Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis. Arthr. and Rheum. 1996; 39: 287-291.

Copyright (c) 2004 Arkhipova D.V., Privalova E.V., Kozlovskaya L.V., Kornev B.M., Popova E.N., Kraeva V.V., Osipenko V.I., Bitsadze V.O.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies